Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Mohakhali, Dhaka, Bangladesh.
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
PLoS One. 2022 Nov 21;17(11):e0277574. doi: 10.1371/journal.pone.0277574. eCollection 2022.
Antimicrobial resistance against shigellosis is increasingly alarming. However, evidence-based knowledge gaps regarding the changing trends of shigellosis in Bangladesh exist due to the scarcity of longitudinal data on antimicrobial resistance. Our study evaluated the last 20 years antimicrobial resistance patterns against shigellosis among under-5 children in the urban and rural sites of Bangladesh. Data were extracted from the Diarrheal Disease Surveillance System (DDSS) of Dhaka Hospital (urban site) and Matlab Hospital (rural site) of the International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) between January 2001 and December 2020. We studied culture-confirmed shigellosis cases from urban Dhaka Hospital (n = 883) and rural Matlab Hospital (n = 1263). Since 2001, a declining percentage of shigellosis in children observed in urban and rural sites. Moreover, higher isolation rates of Shigella were found in the rural site [1263/15684 (8.1%)] compared to the urban site [883/26804 (3.3%)] in the last 20 years. In both areas, S. flexneri was the predominant species. The upward trend of S. sonnei in both the study sites was statistically significant after adjusting for age and sex. WHO-recommended 1st line antibiotic ciprofloxacin resistance gradually reached more than 70% in both the urban and rural site by 2020. In multiple logistic regression after adjusting for age and sex, ciprofloxacin, azithromycin, mecillinam, ceftriaxone, and multidrug resistance (resistance to any two of these four drugs) among under-5 children were found to be increasing significantly (p<0.01) in the last 20 years in both sites. The study results underscore the importance of therapeutic interventions for shigellosis by appropriate drugs based on their current antibiogram for under-5 children. These observations may help policymakers in formulating better case management strategies for shigellosis.
志贺菌病的抗菌药物耐药性日益令人担忧。然而,由于缺乏关于孟加拉国志贺菌病变化趋势的纵向数据,因此基于证据的知识空白仍然存在。我们的研究评估了过去 20 年孟加拉国城市和农村地区 5 岁以下儿童的志贺菌病的抗菌药物耐药模式。数据来自孟加拉国国际腹泻病研究中心(icddr,b)的达卡医院(城市点)和 Matlab 医院(农村点)的腹泻病监测系统(DDSS),时间范围为 2001 年 1 月至 2020 年 12 月。我们研究了城市达卡医院(n = 883)和农村 Matlab 医院(n = 1263)确诊为志贺菌病的病例。自 2001 年以来,城市和农村地区儿童志贺菌病的比例呈下降趋势。此外,在过去的 20 年里,农村地区(1263/15684,8.1%)比城市地区(883/26804,3.3%)分离到更多的志贺菌。在这两个地区,福氏志贺菌是主要的物种。在调整年龄和性别因素后,两个研究地点的宋内志贺菌呈上升趋势,且具有统计学意义。到 2020 年,世界卫生组织推荐的一线抗生素环丙沙星在城市和农村地区的耐药率都逐渐超过了 70%。在调整年龄和性别因素后的多因素逻辑回归分析中,发现 5 岁以下儿童的环丙沙星、阿奇霉素、美西林、头孢曲松和多药耐药(对这四种药物中的两种耐药)在过去 20 年中在两个地区都显著增加(p<0.01)。研究结果强调了根据当前药敏谱为 5 岁以下儿童选择合适药物进行志贺菌病治疗干预的重要性。这些发现可能有助于决策者制定更好的志贺菌病病例管理策略。